Microtest and Antisoma Form Manufacturing Pact

March 30, 2007
Pharmaceutical Technology Editors
ePT--the Electronic Newsletter of Pharmaceutical Technology

Agawam, MA (Mar. 26)-Contract manufacturing and testing laboratory Microtest signed a manufacturing deal with Antisoma to produce AS1411, a new drug being developed for the treatment of various cancers.

Agawam, MA (Mar. 26)-Contract manufacturer and testing laboratory Microtest (www.microtestlabs.com) signed a manufacturing deal with Antisoma (London, www.antisoma.com) to produce AS1411, a new drug being developed to treat various cancers.

Microtest will formulate and aseptically fill and finish AS1411 for Phase II clinical trials. Microtest also will perform stability testing on the product.

Microtest recently invested $7.5 million to expand its pharmaceutical testing services and fill-and-finish contract-manufacturing capabilities. The expansion included new pharmaceutical testing laboratories and new aseptic fill and finish manufacturing facilities.